Document is current
Any future updates will be listed below
-
Authors
Lingvay, Ildiko
Mosenzon, Ofri
Brown, Katelyn
Cui, Xuewei
O’Neill, Ciara
Fernández Landó, Laura
Patel, Hiren
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 12 December 2022
Accepted: 11 March 2023
First Online: 24 March 2023
Declarations
:
: All authors consent to publication.
: Ildiko Lingvay received research funding (paid to institution) from Novo Nordisk, Sanofi, Merck, Pfizer, Mylan and Boehringer Ingelheim. She received advisory/consulting fees and/or other support from: Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Janssen, Intercept, Intarcia, Target Pharma, Merck, Pfizer, Novartis, GI Dynamics, Mylan, Mannkind, Valeritas, Zealand Pharma, Shionogi, Carmot and Bayer. Ofri Mosenzon has received research grant support through Hadassah Hebrew University Hospital, Novo Nordisk and AstraZeneca. She received advisory/consulting fees and/or other support from Novo Nordisk, Eli Lilly and Company, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, AstraZeneca and BOL Pharma. She is on the speaker’s bureau for Novo Nordisk, Eli Lilly and Company, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen. Katelyn Brown, Xuewei Cui, Ciara O’ Neill, Laura Fernández Landó and Hiren Patel are employees and shareholders of Eli Lilly and Company.
